Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lung Capacity01:47

Lung Capacity

56.3K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.3K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

945
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
945
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.5K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.5K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

611
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
611
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.1K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.1K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

521
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
521

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Equitable provision of tuberculosis prevention and care for vulnerable populations.

Bulletin of the World Health Organization·2026
Same author

Tuberculosis research principles and priorities in children and adolescents: an international consensus statement.

The Lancet. Child & adolescent health·2026
Same author

Diabetes screening among people with tuberculosis: a systematic review and meta analysis.

EClinicalMedicine·2026
Same author

Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.

Pulmonology·2026
Same author

Long-term mortality and cause of death in people with tuberculosis compared with matched controls with influenza or non-typhoid salmonellosis in Australia: a retrospective cohort study.

BMJ public health·2026
Same author

Do we need to revise the dose of isoniazid for the treatment of tuberculosis in children?

The European respiratory journal·2026
Same journal

A hypermetabolic pulmonary lesion in a patient with breast cancer.

Breathe (Sheffield, England)·2026
Same journal

Rigid bronchoscopy is the gold standard management of inhaled foreign bodies in children: myth or maxim?

Breathe (Sheffield, England)·2026
Same journal

The price of immune awakening: bridging knowledge gaps in checkpoint inhibitor-related pneumonitis in lung cancer.

Breathe (Sheffield, England)·2026
Same journal

Where are we with biomarkers in paediatric asthma in 2026?

Breathe (Sheffield, England)·2026
Same journal

Recurrent invasive fungal infection with locally advanced thymoma: diagnostic challenges in complex mediastinal disease.

Breathe (Sheffield, England)·2026
Same journal

Elevated <i>D</i> <sub>LCO</sub> and pulmonary function evolution during treatment in a patient with hyperleukocytosis and leukostasis.

Breathe (Sheffield, England)·2026
See all related articles

Related Experiment Video

Updated: Jan 30, 2026

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K

Post-tuberculosis lung disease.

Yasmeen Al-Hindawi1,2, Onno W Akkerman3,4, Anthony Byrne1,2,5

  • 1St Vincent's Health Australia, Heart Lung Clinic, Sydney, Australia.

Breathe (Sheffield, England)
|January 29, 2026
PubMed
Summary
This summary is machine-generated.

Post-TB lung disease (PTLD) causes persistent respiratory issues after tuberculosis treatment, impacting quality of life. Early detection and tailored management are crucial for mitigating PTLD

More Related Videos

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.5K
An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
09:02

An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei

Published on: February 17, 2014

20.3K

Related Experiment Videos

Last Updated: Jan 30, 2026

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K
A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.5K
An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
09:02

An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei

Published on: February 17, 2014

20.3K

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Public Health

Background:

  • Tuberculosis (TB) remains a leading infectious cause of death globally, disproportionately affecting low-income populations.
  • TB-associated lung diseases (TBALD) can occur before, during, or after TB treatment, leading to persistent respiratory impairment.
  • Post-TB lung disease (PTLD) significantly impacts quality of life, social activities, and long-term survival.

Purpose of the Study:

  • To highlight the burden and consequences of TBALD and PTLD.
  • To identify risk factors associated with PTLD development.
  • To outline strategies for PTLD prevention and management.

Main Methods:

  • Literature review and synthesis of current evidence on TBALD and PTLD.
  • Analysis of risk factors including age, smoking, HIV, diagnostic delays, and socioeconomic status.
  • Examination of intervention points for PTLD mitigation across the TB care continuum.

Main Results:

  • PTLD is characterized by persistent respiratory symptoms and lung impairment post-TB treatment.
  • Key risk factors for PTLD include older age, smoking, HIV, delayed diagnosis, and poor socioeconomic conditions.
  • Interventions before, during, and after TB treatment can limit PTLD's impact.

Conclusions:

  • Early detection, clinical assessment, and tailored management are vital for mitigating PTLD-related disability.
  • Healthcare providers and national programs are essential for patient follow-up, education, and integrated care.
  • Sustained funding and research are critical for advancing PTLD care and developing new tools.